(UroToday.com) The advanced bladder cancer in 2021 session of the European Association of Urology annual meeting included a presentation by Dr. Francois Audenet discussing the role of neoadjuvant immunotherapy in muscle-invasive bladder cancer (MIBC). Cisplatin-based chemotherapy before radical cystectomy is the gold standard for localized MIBC, given that it improves overall survival by 5% and disease-free survival by 9%. Recently, there has been a success for immunotherapy for advanced bladder cancer, including in the: